Blood Res.  2021 Mar;56(1):38-43. 10.5045/br.2021.2020189.

Effect of Helicobacter Pylori eradication on patients with ITP: a meta-analysis of studies conducted in the Middle East

• Sadegh Pezeshki SM
• Saki N
• Ghandali MV
• Ekrami A
• Avarvand AY

• KMID: 2514063
• DOI: http://doi.org/10.5045/br.2021.2020189

Abstract

Background
Immune thrombocytopenia (ITP) is a bleeding disorder. Helicobacter Pylori is a Gram-negative bacterium that is presumed to be associated with ITP and therapeutic response of patients. To evaluate the effect of H. Pylori eradication on platelet count of ITP patients, we analyzed the studies conducted on the association between H. Pylori infection and response to therapy in ITP patients in Western Asia focusing on the Middle East region.
Methods
A systematic search of databases (PubMed/Medline, ISI Web of Science, Cochrane Central) and Google Scholar search engine results was conducted up until January 2020. The keywords included in the search were Helicobacter Pylori and/or H. Pylori, ITP and/or immune thrombocytopenia.
Results
Seven studies comprising a total of 228 H. Pylori -infected patients (193 with successful eradication) were included in this study. The association between H. Pylori eradication and ITP was expressed as odds ratios (OR) and 95% confidence intervals (CI). The findings showed that patients who received eradication treatment for H. Pylori infection had significantly higher OR (OR, 8.83; 95% CI, 2.03‒38.35; P =0.004) than those in the non-eradicated group.
Conclusion
Our results indicate a significant therapeutic effect of H. Pylori eradication on the platelet count of patients with chronic ITP. Given the inherent limitations of this study, including the small number of patients, further studies with more patients are recommended.

Keyword

Helicobacter Pylori; H. Pylori; ITP; Immune thrombocytopenia

Figure

• 

  Fig. 1 Identification, screening, eligibility assessment, and final included studies.

• 

  Fig. 2 Odds ratios of the patients with eradication of H. Pylori.

• 

  Fig. 3 Evaluation of publication bias by funnel plot.

Reference

1. Andrès E. 2019; Primary immune thrombocytopenia: a translational research model for autoimmune diseases. J Clin Med. 8:1971. DOI: 10.3390/jcm8111971. PMID: 31739462. PMCID: PMC6912248.

2. Cines DB, Blanchette VS. 2002; Immune thrombocytopenic purpura. N Engl J Med. 346:995–1008. DOI: 10.1056/NEJMra010501. PMID: 11919310. PMCID: PMC7179995.

3. Provan D, Stasi R, Newland AC, et al. 2010; International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 115:168–86. DOI: 10.1182/blood-2009-06-225565. PMID: 19846889. PMCID: PMC6880896.

4. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. 2009; The ITP syndrome: pathogenic and clinical diversity. Blood. 113:6511–21. DOI: 10.1182/blood-2009-01-129155. PMID: 19395674. PMCID: PMC2710913.

5. Cooper N, Ghanima W. 2019; Immune thrombocytopenia. N Engl J Med. 381:945–55. DOI: 10.1056/NEJMcp1810479. PMID: 31483965.

6. Zufferey A, Kapur R, Semple JW. 2017; Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 6:16. DOI: 10.3390/jcm6020016. PMID: 28208757. PMCID: PMC5332920.

7. Pezeshki SMS, Jalali MT, Amin Asnafi A, Jaseb K, Saki N. 2020; HLA-B5, 7, 8, 27, and 51 antigens and immune thrombocytopenic purpura: is there an association? J Pediatr Hematol Oncol. 42:e32–7. DOI: 10.1097/MPH.0000000000001543. PMID: 31233465.

8. Kashiwagi H, Kuwana M, Hato T, et al. 2020; Reference guide for management of adult immune thrombocytopenia in Japan: 2019 revision. Int J Hematol. 111:329–51. DOI: 10.1007/s12185-019-02790-z. PMID: 31897887. PMCID: PMC7223085.

9. Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. 2017; Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 16:620–32. DOI: 10.1016/j.autrev.2017.04.012. PMID: 28428120.

10. Rezaeeyan H, Jaseb K, Kaydani GA, Asnafi AA, Masbi MH, Saki N. 2019; Involvement of interferon-γ + 874A/T polymorphism in the pathogenesis of and therapeutic response to immune thrombo-cytopenia. Lab Med. 50:e42–9. DOI: 10.1093/labmed/lmz010. PMID: 30955035.

11. Rajaei E, Jalali MT, Shahrabi S, Asnafi AA, Pezeshki SMS. 2019; HLAs in autoimmune diseases: dependable diagnostic biomarkers? Curr Rheumatol Rev. 15:269–76. DOI: 10.2174/1573397115666190115143226. PMID: 30644346.

12. Amin Asnafi A, Jalali MT, Pezeshki SMS, Jaseb K, Saki N. 2019; The association between human leukocyte antigens and ITP, TTP, and HIT. J Pediatr Hematol Oncol. 41:81–6. DOI: 10.1097/MPH.0000000000001381. PMID: 30543580.

13. Kim H, Lee WS, Lee KH, et al. 2015; Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombo-cytopenia patients with moderate thrombocytopenia. Ann Hematol. 94:739–46. DOI: 10.1007/s00277-014-2268-9. PMID: 25501820.

14. Aljarad S, Alhamid A, Sankari Tarabishi A, Tarabishi AS, Suliman A, Aljarad Z. 2018; The impact of helicobacter pylori eradication on platelet counts of adult patients with idiopathic thrombocytopenic purpura. BMC Hematol. 18:28. DOI: 10.1186/s12878-018-0119-y. PMID: 30250741. PMCID: PMC6148778.

15. Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. 2016; The effects of helicobacter pylori eradication therapy for chronic idiopathicthrombocytopenic purpura. Gut Liver. 10:356–61. DOI: 10.5009/gnl14483. PMID: 26347517. PMCID: PMC4849687.

16. Brito HS, Braga JA, Loggetto SR, Machado RS, Granato CF, Kawakami E. 2015; Helicobacter pylori infection & immune thrombo-cytopenic purpura in children and adolescents: a randomized controlled trial. Platelets. 26:336–41. DOI: 10.3109/09537104.2014.911836. PMID: 24832381.

17. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. 2010; Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 8:336–41. DOI: 10.1016/j.ijsu.2010.02.007. PMID: 20171303.

18. Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Keshtkar-Jahromi M, Esfahani FS. 2008; Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombo-cytopenic purpura: a controlled trial. Am J Hematol. 83:376–81. DOI: 10.1002/ajh.21125. PMID: 18183613.

19. Maghbool M, Maghbool M, Shahriari M, Karimi M. 2009; Does Helicobacter pylori play a role in the pathogenesis of childhood chronic idiopathic thrombocytopenic purpura? Pediatr Rep. 1:e2. DOI: 10.4081/pr.2009.e2. PMID: 21589818. PMCID: PMC3096032.

20. Payandeh M, Sohrabi N, Zare ME, Kansestani AN, Hashemian AH. 2012; Platelet count response to helicobacter pylori eradication in Iranian patients with idiopathic thrombocytopenic purpura. Mediterr J Hematol Infect Dis. 4:e2012056. DOI: 10.4084/mjhid.2012.056. PMID: 22973500. PMCID: PMC3435127.

21. Payandeh M, Raeisi D, Sohrabi N, et al. 2013; Poor platelet count response to helicobacter pylori eradication in patients with severe idiopathic thrombocytopenic purpura. Int J Hematol Oncol Stem Cell Res. 7:9–14. PMID: 24505529. PMCID: PMC3913150.

22. Sultan S, Irfan SM, Kaker J, Hasan M. 2016; Efficacy of helicobacter pylori eradication as an upfront treatment of secondary immune thrombocytopenia: an experience from Pakistan. Med J Malaysia. 71:53–6. PMID: 27326941.

23. Sheema K, Ikramdin U, Arshi N, Farah N, Imran S. 2017; Role of Helicobacter pylori eradication therapy on platelet recovery in chronic immune thrombocytopenic purpura. Gastroenterol Res Pract. 2017:9529752. DOI: 10.1155/2017/9529752. PMID: 28194178. PMCID: PMC5282406.

24. Sayan O, Akyol Erikci A, Ozturk A. 2006; The efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombo-cytopenic purpura--the first study in Turkey. Acta Haematol. 116:146–9. DOI: 10.1159/000093648. PMID: 16914913.

25. Burucoa C, Axon A. 2017; Epidemiology of Helicobacter pylori infection. Helicobacter. Suppl 1:12403. DOI: 10.1111/hel.12403. PMID: 28891138.

26. Guevara B, Cogdill AG. 2020; Helicobacter pylori: a review of current diagnostic and management strategies. Dig Dis Sci. 65:1917–31. DOI: 10.1007/s10620-020-06193-7. PMID: 32170476.

27. Xie Y, Song C, Cheng H, et al. 2020; Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect. 9:548–57. DOI: 10.1080/22221751.2020.1737579. PMID: 32160805. PMCID: PMC7144303.

28. Thorell K, Lehours P, Vale FF. 2017; Genomics of Helicobacter pylori. Helicobacter. 22 Suppl 1:12409. DOI: 10.1111/hel.12409. PMID: 28891132.

29. Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbințeanu-Braticevici C. 2017; Helicobacter pylori infection: old and new. J Med Life. 10:112–7. PMID: 28616085. PMCID: PMC5467250.

30. Versalovic J. 2003; Helicobacter pylori. Pathology and diagnostic strategies. Am J Clin Pathol. 119:403–12. DOI: 10.1309/5DTF5HT7NPLNA6J5. PMID: 12645343.

31. Hooi JKY, Lai WY, Ng WK, et al. 2017; Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastro-enterology. 153:420–9. DOI: 10.1053/j.gastro.2017.04.022. PMID: 28456631.

32. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. 1998; Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 352:878. DOI: 10.1016/S0140-6736(05)60004-9. PMID: 9742983.

33. Zain MA, Zafar F, Ashfaq A, Jamil AR, Ahmad A. 2019; Helicobacter pylori: an underrated cause of immune thrombocytopenic purpura. A comprehensive review. Cureus. 11:e5551. DOI: 10.7759/cureus.5551. PMID: 31695974. PMCID: PMC6820323.

34. Frydman GH, Davis N, Beck PL, Fox JG. 2015; Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography. Helicobacter. 20:239–51. DOI: 10.1111/hel.12200. PMID: 25728540. PMCID: PMC4506733.

35. Fukuda T, Asou E, Nogi K, Yasuda M, Goto K. 2018; Association between Helicobacter pylori infection and platelet count in mice. Exp Anim. 67:487–92. DOI: 10.1538/expanim.18-0004. PMID: 29877197. PMCID: PMC6219882.

36. Kim BJ, Kim HS, Jang HJ, Kim JH. 2018; Helicobacter pylori eradication in idiopathic thrombocytopenic purpura: a meta-analysis of randomized trials. Gastroenterol Res Pract. 2018:6090878. DOI: 10.1155/2018/6090878. PMID: 30402091. PMCID: PMC6198559.

37. Byrne MF, Kerrigan SW, Corcoran PA, et al. 2003; Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology. 124:1846–54. DOI: 10.1016/S0016-5085(03)00397-4. PMID: 12806618.

38. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. 2007; Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother. 60:237–46. DOI: 10.1093/jac/dkm195. PMID: 17561502.

39. Stasi R, Sarpatwari A, Segal JB, et al. 2009; Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 113:1231–40. DOI: 10.1182/blood-2008-07-167155. PMID: 18945961.